Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor

Thermo Fisher Scientific Inc. has introduced the Gibco CTS DynaXS Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness.

“Cell therapy manufacturers are navigating a rapidly expanding pipeline and increasing regulatory expectations,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “The CTS DynaXS bioreactor reflects our commitment to help deliver end-to-end, integrated solutions that enable customers to simplify scale-up, strengthen process control, and support the development of therapies intended for patient use.”

The CTS DynaXS Single Use Bioreactor was designed specifically to address the evolving needs of the cell therapy landscape. The stirred-tank, single-use system supports cell expansion across development and early clinical volumes, offering a scalable platform from small process development batches to larger cGMP manufacturing runs.

The CTS DynaXS bioreactor extends Thermo Fisher’s Cell Therapy Systems (CTS) portfolio, supporting workflows from cell isolation and activation through expansion and downstream processing. This integration enables customers to build modular, scalable manufacturing strategies with unified technical support and regulatory documentation.

“Manufacturers want platforms that grow with them,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types.”